FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079183773> ?p ?o ?g. }

• W2079183773 endingPage "1903" @default.
• W2079183773 startingPage "1903" @default.
• W2079183773 abstract "Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease.A randomized, double-blind, placebo-controlled trial of DHA supplementation in individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores, 14-26) was conducted between November 2007 and May 2009 at 51 US clinical research sites of the Alzheimer's Disease Cooperative Study.Participants were randomly assigned to algal DHA at a dose of 2 g/d or to identical placebo (60% were assigned to DHA and 40% were assigned to placebo). Duration of treatment was 18 months.Change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR) sum of boxes. Rate of brain atrophy was also determined by volumetric magnetic resonance imaging in a subsample of participants (n = 102).A total of 402 individuals were randomized and a total of 295 participants completed the trial while taking study medication (DHA: 171; placebo: 124). Supplementation with DHA had no beneficial effect on rate of change on ADAS-cog score, which increased by a mean of 7.98 points (95% confidence interval [CI], 6.51-9.45 points) for the DHA group during 18 months vs 8.27 points (95% CI, 6.72-9.82 points) for the placebo group (linear mixed-effects model: P = .41). The CDR sum of boxes score increased by 2.87 points (95% CI, 2.44-3.30 points) for the DHA group during 18 months compared with 2.93 points (95% CI, 2.44-3.42 points) for the placebo group (linear mixed-effects model: P = .68). In the subpopulation of participants (DHA: 53; placebo: 49), the rate of brain atrophy was not affected by treatment with DHA. Individuals in the DHA group had a mean decline in total brain volume of 24.7 cm(3) (95% CI, 21.4-28.0 cm(3)) during 18 months and a 1.32% (95% CI, 1.14%-1.50%) volume decline per year compared with 24.0 cm(3) (95% CI, 20-28 cm(3)) for the placebo group during 18 months and a 1.29% (95% CI, 1.07%-1.51%) volume decline per year (P = .79).Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease.clinicaltrials.gov Identifier: NCT00440050." @default.
• W2079183773 created "2016-06-24" @default.
• W2079183773 creator A5000277793 @default.
• W2079183773 creator A5005099850 @default.
• W2079183773 creator A5029958756 @default.
• W2079183773 creator A5034207242 @default.
• W2079183773 creator A5034225628 @default.
• W2079183773 creator A5040374029 @default.
• W2079183773 creator A5043086041 @default.
• W2079183773 creator A5059885659 @default.
• W2079183773 creator A5068057129 @default.
• W2079183773 creator A5069838055 @default.
• W2079183773 creator A5084326649 @default.
• W2079183773 creator A5085009648 @default.
• W2079183773 date "2010-11-03" @default.
• W2079183773 modified "2023-10-14" @default.
• W2079183773 title "Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease" @default.
• W2079183773 cites W1847168837 @default.
• W2079183773 cites W1940333572 @default.
• W2079183773 cites W1953027527 @default.
• W2079183773 cites W1982447059 @default.
• W2079183773 cites W1982816514 @default.
• W2079183773 cites W1984042519 @default.
• W2079183773 cites W1990559218 @default.
• W2079183773 cites W1991084221 @default.
• W2079183773 cites W1991619604 @default.
• W2079183773 cites W1991952617 @default.
• W2079183773 cites W1996776294 @default.
• W2079183773 cites W1998932116 @default.
• W2079183773 cites W2014208353 @default.
• W2079183773 cites W2017776734 @default.
• W2079183773 cites W2018671066 @default.
• W2079183773 cites W2030711203 @default.
• W2079183773 cites W2037099926 @default.
• W2079183773 cites W2045504209 @default.
• W2079183773 cites W2065945635 @default.
• W2079183773 cites W2078524519 @default.
• W2079183773 cites W2089868121 @default.
• W2079183773 cites W2094472277 @default.
• W2079183773 cites W2098071975 @default.
• W2079183773 cites W2104285446 @default.
• W2079183773 cites W2106888831 @default.
• W2079183773 cites W2108563688 @default.
• W2079183773 cites W2109348896 @default.
• W2079183773 cites W2111963393 @default.
• W2079183773 cites W2118502261 @default.
• W2079183773 cites W2124956656 @default.
• W2079183773 cites W2131422017 @default.
• W2079183773 cites W2139747033 @default.
• W2079183773 cites W2149944282 @default.
• W2079183773 cites W2152586909 @default.
• W2079183773 cites W2158226583 @default.
• W2079183773 cites W2165711752 @default.
• W2079183773 cites W2167230895 @default.
• W2079183773 cites W2168895330 @default.
• W2079183773 cites W2193764494 @default.
• W2079183773 cites W35662498 @default.
• W2079183773 doi "https://doi.org/10.1001/jama.2010.1510" @default.
• W2079183773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3259852" @default.
• W2079183773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21045096" @default.
• W2079183773 hasPublicationYear "2010" @default.
• W2079183773 type Work @default.
• W2079183773 sameAs 2079183773 @default.
• W2079183773 citedByCount "641" @default.
• W2079183773 countsByYear W20791837732012 @default.
• W2079183773 countsByYear W20791837732013 @default.
• W2079183773 countsByYear W20791837732014 @default.
• W2079183773 countsByYear W20791837732015 @default.
• W2079183773 countsByYear W20791837732016 @default.
• W2079183773 countsByYear W20791837732017 @default.
• W2079183773 countsByYear W20791837732018 @default.
• W2079183773 countsByYear W20791837732019 @default.
• W2079183773 countsByYear W20791837732020 @default.
• W2079183773 countsByYear W20791837732021 @default.
• W2079183773 countsByYear W20791837732022 @default.
• W2079183773 countsByYear W20791837732023 @default.
• W2079183773 crossrefType "journal-article" @default.
• W2079183773 hasAuthorship W2079183773A5000277793 @default.
• W2079183773 hasAuthorship W2079183773A5005099850 @default.
• W2079183773 hasAuthorship W2079183773A5029958756 @default.
• W2079183773 hasAuthorship W2079183773A5034207242 @default.
• W2079183773 hasAuthorship W2079183773A5034225628 @default.
• W2079183773 hasAuthorship W2079183773A5040374029 @default.
• W2079183773 hasAuthorship W2079183773A5043086041 @default.
• W2079183773 hasAuthorship W2079183773A5059885659 @default.
• W2079183773 hasAuthorship W2079183773A5068057129 @default.
• W2079183773 hasAuthorship W2079183773A5069838055 @default.
• W2079183773 hasAuthorship W2079183773A5084326649 @default.
• W2079183773 hasAuthorship W2079183773A5085009648 @default.
• W2079183773 hasBestOaLocation W20791837732 @default.
• W2079183773 hasConcept C126322002 @default.
• W2079183773 hasConcept C142724271 @default.
• W2079183773 hasConcept C168563851 @default.
• W2079183773 hasConcept C178790620 @default.
• W2079183773 hasConcept C185592680 @default.
• W2079183773 hasConcept C19038510 @default.
• W2079183773 hasConcept C204787440 @default.
• W2079183773 hasConcept C27081682 @default.

• next